Reviewing Dominari (NASDAQ:DOMH) & Lion Group (NASDAQ:LGHL)

Volatility and Risk

Lion Group has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, Dominari has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Earnings & Valuation

This table compares Lion Group and Dominari”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lion Group	$19.93 million	0.03	-$5.26 million	N/A	N/A
Dominari	$12.59 million	0.83	-$22.88 million	($3.87)	-0.43

Lion Group has higher revenue and earnings than Dominari.

Profitability

This table compares Lion Group and Dominari’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lion Group	N/A	N/A	N/A
Dominari	-180.22%	-32.89%	-29.47%

Institutional & Insider Ownership

0.2% of Lion Group shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 8.7% of Lion Group shares are owned by insiders. Comparatively, 36.7% of Dominari shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Lion Group beats Dominari on 6 of the 9 factors compared between the two stocks.

About Lion Group

Lion Group Holding Ltd., together with its subsidiaries, operates a trading platform for corporate clients, individual traders, and retail investors primarily in the People's Republic of China and Southeast Asia. Its trading platform offers a range of products and services comprising contracts for difference trading, over-the-counter stock options trading, futures and securities brokerage, and total return swap trading services through its Lion Brokers Pro app platform. The company's trading platform allows users to trade various futures products on futures exchanges worldwide, including the Chicago Mercantile Exchange, Singapore Exchange, the Hong Kong Futures Exchange, and Eurex Exchange; stocks listed on the New York Stock Exchange, Nasdaq and Hong Kong Stock Exchange; and the People's Republic of China stocks listed on the Shanghai Stock Exchange and Shenzhen Stock Exchange that are eligible for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs. It markets its products mainly through search engines, social media, app stores, and third-party websites. Lion Group Holding Ltd. was founded in 2015 and is headquartered in Singapore.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.